| Revue: | Brazilian Journal of Pharmaceutical Sciences |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000451566 |
| ISSN: | 1984-8250 |
| Autores: | Wang, Dawei1 Fan, Ceji1 Tang, Jun1 |
| Instituciones: | 1Wuhan Huaxia University of Technology, School of Biological and Pharmaceutical Engineering, Wuhan, Hubei. China |
| Año: | 2021 |
| Volumen: | 57 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Experimental, aplicado |
| Resumen en inglés | This study investigated the mechanism underlying the suppression of estrogen receptor-positive MCF-7 cell growth by regorafenib. MCF-7 cells were treated with regorafenib, and the effect of regorafenib on multiple cancer-associated pathways was evaluated. Although regorafenib effectively inhibited the proliferation of MCF-7 cells, it had no effect on the proliferation of the normal breast epithelial cell line MCF10A. Regorafenib suppressed MCF-7 cell migration, probably by regulating the homeostatic expression of matrix metalloproteinases and the tissue inhibitor of MMPs. Furthermore, it upregulated p21 expression, downregulated cyclin B1 and cyclin D1 expresssions, and caused cell cycle arrest. In addition, regorafenib induced apoptosis in MCF-7 cells by reducing Mcl-1 expression and activating caspase signaling. These results demonstrate that regorafenib has the potential to be an effective drug for treating breast cancer |
| Disciplinas: | Química, Medicina |
| Palabras clave: | Oncología, Farmacología, Medicina experimental, Cáncer, Mama, Regorafenib, Apoptosis, Metaloproteinasas, Expresión génica |
| Keyword: | Oncology, Pharmacology, Experimental medicine, Cancer, Breast, Regorafenib, Apoptosis, Metalloproteinases, Gene expression |
| Texte intégral: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
